Summary
16.38 -0.67(-3.93%)10/04/2024
Evolus Inc (EOLS)
Evolus Inc (EOLS)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -3.96 | 2.70 | 6.36 | 50.14 | 21.97 | 94.31 | 9.13 | 42.43 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 16.38 | |
| Open | 17.05 | |
| High | 17.18 | |
| Low | 16.34 | |
| Volume | 411,631 | |
| Change | -0.68 | |
| Change % | -3.96 | |
| Avg Volume (20 Days) | 442,383 | |
| Volume/Avg Volume (20 Days) Ratio | 0.93 | |
| 52 Week Range | 7.44 - 17.70 | |
| Price vs 52 Week High | -7.46% | |
| Price vs 52 Week Low | 120.16% | |
| Range | -3.93 | |
| Gap Up/Down | -0.54 | |
Fundamentals | ||
| Market Capitalization (Mln) | 1,032 | |
| EBIDTA | -76,411,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 15.14 | |
| Book Value | 1.7530 | |
| Earnings Per Share | -3.1450 | |
| EPS Estimate Current Quarter | -0.2700 | |
| EPS Estimate Next Quarter | -0.2400 | |
| EPS Estimate Current Year | -0.9800 | |
| EPS Estimate Next Year | -0.6100 | |
| Diluted EPS (TTM) | -3.1450 | |
| Revenues | ||
| Profit Marging | -1.6278 | |
| Operating Marging (TTM) | -0.7542 | |
| Return on asset (TTM) | -0.1872 | |
| Return on equity (TTM) | -2.1031 | |
| Revenue TTM | 85,593,000 | |
| Revenue per share TTM | 1.9320 | |
| Quarterly Revenue Growth (YOY) | 0.5110 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 38,241,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 3.1724 | |
| Revenue Enterprise Value | 2.6276 | |
| EBITDA Enterprise Value | 0.1166 | |
| Shares | ||
| Shares Outstanding | 55,577,000 | |
| Shares Float | 36,555,764 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 33.46 | |
| Institutions (%) | 34.53 | |
09/27 21:00 EST - businesswire.com
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of an aggregate of 10,845 restricted stock units (RSUs) of the company's common stock to 5 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of directors under the Evolus' 2023 Inducement Incentive Plan, with a grant date of Sep.
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of an aggregate of 10,845 restricted stock units (RSUs) of the company's common stock to 5 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of directors under the Evolus' 2023 Inducement Incentive Plan, with a grant date of Sep.
07/31 22:22 EST - seekingalpha.com
Evolus, Inc. (EOLS) Q2 2024 Earnings Call Transcript
Evolus, Inc. (NASDAQ:EOLS ) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Nareg Sagherian - Vice President and Head of Global Investor Relations and Corporate Communications David Moatazedi - President and CEO Sandra Beaver - CFO Rui Avelar - Chief Medical Officer and Head of R&D Conference Call Participants Jack Padovano - Stifel Navann Ty - BNP Serge Belanger - Needham & Company Operator Good afternoon, everyone and thank you for standing by. Welcome to Evolus' Second Quarter 2024 Earnings Conference Call.
Evolus, Inc. (EOLS) Q2 2024 Earnings Call Transcript
Evolus, Inc. (NASDAQ:EOLS ) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Nareg Sagherian - Vice President and Head of Global Investor Relations and Corporate Communications David Moatazedi - President and CEO Sandra Beaver - CFO Rui Avelar - Chief Medical Officer and Head of R&D Conference Call Participants Jack Padovano - Stifel Navann Ty - BNP Serge Belanger - Needham & Company Operator Good afternoon, everyone and thank you for standing by. Welcome to Evolus' Second Quarter 2024 Earnings Conference Call.
07/31 19:46 EST - zacks.com
Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates
Evolus, Inc. (EOLS) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.22 per share a year ago.
Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates
Evolus, Inc. (EOLS) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.22 per share a year ago.
07/31 16:09 EST - reuters.com
Evolus reports first-ever adjusted profit in Q2 fueled by strong sales of Botox rival
Evolus , an anti-wrinkle injection maker, reported its first-ever quarterly profit on an adjusted basis on Wednesday, driven by strong sales of its Botox rival Jeuveau.
Evolus reports first-ever adjusted profit in Q2 fueled by strong sales of Botox rival
Evolus , an anti-wrinkle injection maker, reported its first-ever quarterly profit on an adjusted basis on Wednesday, driven by strong sales of its Botox rival Jeuveau.
07/31 16:05 EST - investors.com
Evolus, A Medical Aesthetics Player, Becomes Profitable — Two Quarters Early
Medical aesthetics company Evolus notched its first-ever profits late Wednesday — two quarters ahead of expectations.
Evolus, A Medical Aesthetics Player, Becomes Profitable — Two Quarters Early
Medical aesthetics company Evolus notched its first-ever profits late Wednesday — two quarters ahead of expectations.
07/17 08:00 EST - businesswire.com
Evolus to Report Second Quarter Financial Results on July 31, 2024
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its second quarter 2024 financial results on Wednesday, July 31, 2024, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks. To.
Evolus to Report Second Quarter Financial Results on July 31, 2024
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its second quarter 2024 financial results on Wednesday, July 31, 2024, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks. To.
06/24 08:00 EST - businesswire.com
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it has submitted the final module of its premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the Evolysse™ Lift and Evolysse™ Smooth dermal filler products for the nasolabial fold (NLF). “We are pleased to have submitted the final module of the PMA application,” said Dr. Rui.
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it has submitted the final module of its premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the Evolysse™ Lift and Evolysse™ Smooth dermal filler products for the nasolabial fold (NLF). “We are pleased to have submitted the final module of the PMA application,” said Dr. Rui.
06/12 08:00 EST - businesswire.com
Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company focused on building an aesthetic portfolio, has commercially launched Nuceiva® (botulinum toxin type A) in Spain. The product is now available for direct order and delivery to Spanish medical aesthetics healthcare professionals. Nuceiva® is approved by the European Commission for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum fr.
Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company focused on building an aesthetic portfolio, has commercially launched Nuceiva® (botulinum toxin type A) in Spain. The product is now available for direct order and delivery to Spanish medical aesthetics healthcare professionals. Nuceiva® is approved by the European Commission for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum fr.
05/21 12:01 EST - zacks.com
Evolus (EOLS) Releases Favorable Dermal Fillers Study Data
The addition of Evolysse fillers to the company's portfolio complements Evolus' (EOLS) flagship neurotoxin Jeuveau.
Evolus (EOLS) Releases Favorable Dermal Fillers Study Data
The addition of Evolysse fillers to the company's portfolio complements Evolus' (EOLS) flagship neurotoxin Jeuveau.
05/20 08:30 EST - businesswire.com
Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced positive topline results from a U.S. pivotal nasolabial fold (NLF) study of dermal filler products Evolysse™ Lift and Smooth. Data were presented at the 2024 SCALE Meeting on May 17, 2024, in Nashville. “Achieving positive topline results in our NLF study is a pivotal step supporting the upcoming submission of our P.
Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced positive topline results from a U.S. pivotal nasolabial fold (NLF) study of dermal filler products Evolysse™ Lift and Smooth. Data were presented at the 2024 SCALE Meeting on May 17, 2024, in Nashville. “Achieving positive topline results in our NLF study is a pivotal step supporting the upcoming submission of our P.
05/15 08:30 EST - businesswire.com
Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women's Wear Daily Beauty CEO Summit
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its participation in the Women's Wear Daily (WWD) Beauty CEO Summit. This summit brings together the leading retailers, marketers, and creative minds across all categories to help prepare for the next phase of global beauty while driving growth and innovation today. At the global consumer beauty event, President and.
Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women's Wear Daily Beauty CEO Summit
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its participation in the Women's Wear Daily (WWD) Beauty CEO Summit. This summit brings together the leading retailers, marketers, and creative minds across all categories to help prepare for the next phase of global beauty while driving growth and innovation today. At the global consumer beauty event, President and.
05/10 09:10 EST - businesswire.com
Evolus' Sandra Beaver Named Orange County Business Journal's Public Company CFO of the Year
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that its Chief Financial Officer, Sandra Beaver, has been awarded Outstanding CFO of a Public Company by the Orange County Business Journal. The award is given to CFOs for outstanding performance as corporate stewards. Since joining Evolus in 2022, Mrs. Beaver has played a critical role in positioning the company fo.
Evolus' Sandra Beaver Named Orange County Business Journal's Public Company CFO of the Year
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that its Chief Financial Officer, Sandra Beaver, has been awarded Outstanding CFO of a Public Company by the Orange County Business Journal. The award is given to CFOs for outstanding performance as corporate stewards. Since joining Evolus in 2022, Mrs. Beaver has played a critical role in positioning the company fo.
05/07 23:27 EST - seekingalpha.com
Evolus, Inc. (EOLS) Q1 2024 Earnings Call Transcript
Evolus, Inc. (NASDAQ:EOLS ) Q3 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Nareg Sagherian - VP and Head, Global IR and Corporate Communications David Moatazedi - President and CEO Rui Avelar - CMO and Head, Research & Development Sandra Beaver - CFO Conference Call Participants Annabel Samimy - Stifel Marc Goodman - Leerink Navann Ty - BNP Paribas Uy Ear - Mizuho Securities Doug Tsao - H.C. Wainwright Serge Belanger - Needham & Company Operator Good afternoon everyone and thank you for standing by.
Evolus, Inc. (EOLS) Q1 2024 Earnings Call Transcript
Evolus, Inc. (NASDAQ:EOLS ) Q3 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Nareg Sagherian - VP and Head, Global IR and Corporate Communications David Moatazedi - President and CEO Rui Avelar - CMO and Head, Research & Development Sandra Beaver - CFO Conference Call Participants Annabel Samimy - Stifel Marc Goodman - Leerink Navann Ty - BNP Paribas Uy Ear - Mizuho Securities Doug Tsao - H.C. Wainwright Serge Belanger - Needham & Company Operator Good afternoon everyone and thank you for standing by.
05/07 19:35 EST - zacks.com
Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates
Evolus, Inc. (EOLS) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.17 per share a year ago.
Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates
Evolus, Inc. (EOLS) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.17 per share a year ago.
05/07 16:05 EST - businesswire.com
Evolus Reports First Quarter 2024 Results and Provides Business Update
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported financial results for the first quarter ended March 31, 2024, and provided a business update. “Coming off a record year in 2023, we're proud to carry the momentum into 2024 with our first quarter performance multiples above the market,” said David Moatazedi, President and Chief Executive Officer. “We are building a p.
Evolus Reports First Quarter 2024 Results and Provides Business Update
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported financial results for the first quarter ended March 31, 2024, and provided a business update. “Coming off a record year in 2023, we're proud to carry the momentum into 2024 with our first quarter performance multiples above the market,” said David Moatazedi, President and Chief Executive Officer. “We are building a p.
05/03 08:26 EST - zacks.com
4 Stocks to Keep a Tab on for Amazing Earnings Acceleration
Notable companies to have witnessed solid earnings acceleration as of now are Sana Biotechnology (SANA), LifeMD (LFMD), Evolus (EOLS) and Expro Group Holdings (XPRO).
4 Stocks to Keep a Tab on for Amazing Earnings Acceleration
Notable companies to have witnessed solid earnings acceleration as of now are Sana Biotechnology (SANA), LifeMD (LFMD), Evolus (EOLS) and Expro Group Holdings (XPRO).
04/25 08:01 EST - zacks.com
3 Top Stocks to Invest in for Amazing Earnings Acceleration
Invest in companies such as Zymeworks (ZYME), Evolus (EOLS) and Bilibili (BILI) for superb earnings acceleration.
3 Top Stocks to Invest in for Amazing Earnings Acceleration
Invest in companies such as Zymeworks (ZYME), Evolus (EOLS) and Bilibili (BILI) for superb earnings acceleration.